Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

15.22EUR
18 Mar 2019
Change (% chg)

-- (--)
Prev Close
€15.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
208,241
52-wk High
€18.00
52-wk Low
€9.06

Latest Key Developments (Source: Significant Developments)

NICE Provisionally Approves Almirall's Ilumetri For Adults With Plaque Psoriasis In UK
Friday, 8 Mar 2019 

March 8 (Reuters) - Almirall SA ::NICE PROVISIONALLY APPROVES ILUMETRI AS COST EFFECTIVE OPTION FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN UK.  Full Article

Almirall Enters Into Definitive Agreement To Divest ThermiGen
Monday, 4 Mar 2019 

March 4 (Reuters) - Almirall SA ::SAYS ENTERS INTO DEFINITIVE AGREEMENT TO DIVEST THERMIGEN, ITS MEDICAL DEVICE AESTHETICS BUSINESS.SIGNS DEAL WITH CELLING BIOSCIENCES FOR THERMIGEN, TRANSACTION IS EXPECTED TO CLOSE BEFORE OR ON MARCH 29.SAYS TRANSACTION DOES NOT AFFECT ALMIRALL GUIDANCE FOR 2019.  Full Article

Almirall-Nuevolution Partnership Achieves First Collaboration Milestone For Dermatology Diseases
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Almirall SA ::ALMIRALL-NUEVOLUTION PARTNERSHIP ACHIEVES FIRST COLLABORATION MILESTONE FOR DERMATOLOGY DISEASES.THE POSITIVE RESULT TRIGGERED A CONTRACTUAL MILESTONE TO NUEVOLUTION.MILESTONE DATA ACHIEVED SUPPORTS A PROGRAM WITH A CANDIDATE DRUG HAVING BEST-IN-CLASS POTENTIAL.  Full Article

Almirall FY Net Result Swings To Profit Of 77.7 Mln Euros
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Almirall SA ::FY EBITDA 209.5 MILLION EUROS VERSUS 142.2 MILLION EUROS YEAR AGO.FY NORMALIZED NET PROFIT 88.2 MILLION EUROS VERSUS 27.1 MILLION EUROS YEAR AGO.FY REVENUE 811.0 MILLION EUROS VERSUS 755.8 MILLION EUROS YEAR AGO.2019 GUIDANCE : TOTAL REVENUES TO GROW AT LOW DOUBLE-DIGIT AND EBITDA TO REACH €290-€300 MILLION (VERSUS. 2018).FY RESEARCH AND DEVELOPMENT EXPENSES 87.6 MILLION EUROS VERSUS 87.9 MILLION EUROS YEAR AGO.FY NET PROFIT 77.7 MILLION EUROS VERSUS LOSS 304.0 MILLION EUROS YEAR AGO.  Full Article

Almirall H1 Net Result Turns To Profit Of 52 Mln Euros YoY
Monday, 30 Jul 2018 

July 30 (Reuters) - Almirall SA ::H1 NET PROFIT 52.0 MILLION EUROS VERSUS LOSS 73.1 MILLION EUROS YEAR AGO.H1 EBITDA 105.5 MILLION EUROS VERSUS 58.6 MILLION EUROS YEAR AGO.H1 REVENUE 398.3 MILLION EUROS VERSUS 378.9 MILLION EUROS YEAR AGO.UPGRADES 2018 EBITDA GUIDANCE, NOW SEES YOY GROWTH C. 30% VERSUS ORIGINAL EBITDA FORECAST OF C. 20% GROWTH.CONFIRMS TOTAL REVENUE GUIDANCE FOR 2018.SEES DECLINE IN SALES AT THERMIGEN, DUE TO EARLY TERMINATION OF INSTALIFTTM AGREEMENT AND POOR PERFORMANCE OF CAPITAL SALES.  Full Article

Almirall: Both Phase III Trials Of KX2-391 For Actinic Keratosis Achieve Primary Endpoint
Thursday, 26 Jul 2018 

July 26 (Reuters) - Almirall SA ::ANNOUNCES THAT BOTH PHASE III TRIALS OF KX2- 391 FOR ACTINIC KERATOSIS ACHIEVED PRIMARY ENDPOINT.  Full Article

Almirall: Phase III Trial Of P3074 Positive, Phase II Review Of PAT001 Didn't Meet Criteria
Monday, 25 Jun 2018 

June 25 (Reuters) - Almirall SA ::SAYS TOP-LINE RESULTS OF PHASE III TRIAL OF P3074 (ANDROGENETIC ALOPECIA) WERE POSITIVE.SAYS PHASE II REVIEW OF PAT001 (ICHTHYOSIS) DID NOT MEET ALMIRALL’S INTERNAL DEVELOPMENT CRITERIA.SAYS REST OF CO’S RESEARCH AND DEVELOPMENT PIPELINE IS PROGRESSING AS EXPECTED.  Full Article

Almirall Signs Distribution Agreement With AstraZeneca For Crestor And Provisacor In Spain
Friday, 22 Dec 2017 

Dec 22 (Reuters) - ALMIRALL SA ::EXECUTES LICENSE AND SUPPLY AGREEMENT WITH ASTRAZENECA FOR CRESTOR AND PROVISACOR (ROSUVASTATIN).LICENSE AGREEMENT GRANTS ALMIRALL EXCLUSIVE RIGHTS TO COMMERCIALIZE CRESTOR AND PROVISACOR IN SPAIN.  Full Article

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALMIRALL SA ::ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​.TUDORZA REDUCES CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND DEMONSTRATES CARDIOVASCULAR SAFETY.‍​.  Full Article